Toronto Innovation Acceleration Partners

Grey Matter Neurosciences is a neurotechnology company specializing in the development of innovative medical devices and drug-device combinations to address age-related brain disorders, with a primary focus on dementia. Their flagship technology is a portable ultrasound helmet, designed to non-invasively enhance brain function in seniors with Alzheimer's disease.

Radiant Biotherapeutics is an innovative biotechnology company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by creating multi-functional biologics designed to address challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging the principles of avidity and enhanced binding power, Radiant Biotherapeutics enables healthcare professionals to deliver potent therapies that have the potential to transform treatment outcomes for patients. The company's commitment to pioneering these advanced therapeutics positions it at the forefront of the biotherapeutics field, striving to unlock new avenues for patient care.

HDAX Therapeutics is focused on developing innovative small molecule therapeutics aimed at treating conditions driven by HDAC6, particularly in the realms of cardiovascular and neurological diseases. The company employs a unique two-site binding mechanism in its targeted therapeutics platform, which enhances the safety and efficacy of treatments while addressing significant unmet medical needs. By concentrating on the root causes of these diseases, HDAX Therapeutics strives to improve patient outcomes and provide long-lasting solutions for various pathologies, including neuropathies and cardiometabolic disorders.

AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, founded in 2016. The company is focused on developing an innovative injectable hydrogel platform technology designed to enhance drug delivery and improve patient outcomes in various medical applications, particularly in post-surgical pain management, cancer treatment, and other challenging therapeutic areas. AmacaThera's technology features a unique fast-gelling material that liquefies under mechanical force, consisting of a reversible blend of hyaluronan and methylcellulose. This approach allows for localized and sustained drug delivery, potentially reducing postoperative pain and addressing other medical needs effectively.

Spero Analytics specializes in designing and deploying wireless mesh networks for continuous environmental monitoring in remote and off-grid locations. Their scalable sensor arrays, capable of covering vast areas and adapting to various sensor types, require no telecommunications infrastructure. Key features include self-healing network capabilities and cold climate adaptability, reducing maintenance burden. The company focuses on automated greenhouse gas monitoring in landfills, with installations in Ontario, and is expanding to petroleum facilities and potash mines through collaborations with Environment Canada and proof-of-concept projects. Spero Analytics has raised $210,000, secured design partners, and made sales to government and international clients. Their mission is to become the industry standard for remote environmental monitoring.

Medly offers an AI-powered platform for managing multiple chronic conditions. Medly's vision is to become the leading platform for managing multiple chronic conditions (MCCs), with identified target conditions including Heart Failure, Depression (Mental Health), Diabetes, and Hypertension.

Radiant Biotherapeutics is an innovative biotechnology company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by creating multi-functional biologics designed to address challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging the principles of avidity and enhanced binding power, Radiant Biotherapeutics enables healthcare professionals to deliver potent therapies that have the potential to transform treatment outcomes for patients. The company's commitment to pioneering these advanced therapeutics positions it at the forefront of the biotherapeutics field, striving to unlock new avenues for patient care.

Medly offers an AI-powered platform for managing multiple chronic conditions. Medly's vision is to become the leading platform for managing multiple chronic conditions (MCCs), with identified target conditions including Heart Failure, Depression (Mental Health), Diabetes, and Hypertension.

NerveX Neurotechnologies specializes in the development of advanced neuromodulation devices aimed at repairing and enhancing the nervous system. Its flagship product, ANIMO, is an adaptive neural implant that integrates proprietary machine learning and responsive electrical neuromodulation technology. This innovative device is designed to improve sensory functions and assist in the treatment of conditions such as canine epilepsy disorder, providing solutions that can significantly benefit both animals and potentially humans. Through its focus on intelligent neuromodulation, NerveX is positioned at the forefront of neurotechnology, striving to transform the landscape of neurological healthcare.

Genetics Adviser is a digital health company that offers a web-based platform designed to enhance genetic counseling services. The platform provides patients with access to educational content and resources, enabling them to better understand their genetic health before consulting with clinicians. This pre-consultation preparation allows for more efficient and patient-centered clinical interactions, as complex information can be reviewed at home, reserving clinical time for personalized discussions. The platform also facilitates secure messaging between patients and clinicians, and enables patients to download summaries of their sessions and results.

Mazlite specializes in providing an Industrial IoT platform tailored for spray monitoring and digitization in hazardous environments. The company's technology includes IoT sensors for imaging, web-based software, real-time analytics powered by AI, and cloud-based data management. This platform is primarily used by automotive paint and pharmaceutical manufacturers to enhance product quality, improve sustainability, minimize material and energy waste, and reduce scraps and repairs.

Damona Pharmaceuticals is a pre-clinical pharmaceutical company focused on treating and preventing cognitive deficits associated with various brain disorders and aging. The company develops small molecule therapeutics aimed at transforming the treatment of cognitive symptoms and restoring normal life functions for underserved and understudied mental health and aging populations. Their goal is to enable patients to potentially reverse impairments and resolve previously unresolvable symptoms.

Damona Pharmaceuticals is a pre-clinical pharmaceutical company focused on treating and preventing cognitive deficits associated with various brain disorders and aging. The company develops small molecule therapeutics aimed at transforming the treatment of cognitive symptoms and restoring normal life functions for underserved and understudied mental health and aging populations. Their goal is to enable patients to potentially reverse impairments and resolve previously unresolvable symptoms.

Pearl Interactives is focused on co-creating interactive media that fosters wellness, play, and learning for children of all abilities. The company specializes in developing innovative platforms that incorporate musical play and learning experiences. Its flagship product, Bootle Blast, is a video game system utilizing mixed reality technology to engage children and youth with neuromotor conditions in exercises aimed at improving their functional abilities. By offering interactive games that are accessible and touch-free, Pearl Interactives aims to reduce anxiety and promote shared musical play, thereby enhancing the developmental experience for young children.

Tabiat operates a software-as-a-service platform that specializes in artificial intelligence-driven remote patient monitoring. The platform is designed to enhance patient outcomes by providing actionable insights that assist healthcare professionals in clinical decision-making. By delivering timely and relevant data, Tabiat enables clinicians to effectively monitor their patients and prioritize care for those in greatest need. This innovative approach not only improves the quality of care but also helps to reduce hospitalizations and associated costs, ultimately allowing healthcare providers to manage more patients efficiently while generating additional revenue.

PhenoTips is a computer software company based in Ontario, Canada, that specializes in solutions for clinical genetics and phenotyping. Founded in 2014, the company develops software designed to enhance diagnostic accuracy and standardize the recording of phenotypes. Its products are tailored for clinical environments and can be seamlessly integrated with existing electronic health records. By leveraging advanced technology, PhenoTips aims to support healthcare professionals in utilizing genomic medicine for improved clinical decision-making and diagnosis.

PhenoTips is a computer software company based in Ontario, Canada, that specializes in solutions for clinical genetics and phenotyping. Founded in 2014, the company develops software designed to enhance diagnostic accuracy and standardize the recording of phenotypes. Its products are tailored for clinical environments and can be seamlessly integrated with existing electronic health records. By leveraging advanced technology, PhenoTips aims to support healthcare professionals in utilizing genomic medicine for improved clinical decision-making and diagnosis.

Quantum Bridge is a company dedicated to enhancing secure communication through the development of proprietary software and quantum repeater hardware. It aims to provide organizations with robust security solutions for encrypting and communicating highly confidential and classified information. By focusing on the commercialization of quantum and quantum-inspired products, Quantum Bridge seeks to enable secure communication and distributed symmetric key exchange, along with a key distribution and management system designed to ensure quantum-safe communications. Its innovations are intended to bolster the resilience of current networks, offering unbreakable security for both network and endpoint protection.

Bright Angel Therapeutics is a biopharmaceutical company focused on developing innovative treatments for drug-resistant and life-threatening fungal infections. The company aims to enhance the efficacy of existing antifungal therapies and combat drug resistance by specifically targeting the stress responses that fungi rely on for survival, virulence, and resistance to treatment. By addressing the challenges posed by the frequent emergence of clinical resistance, Bright Angel Therapeutics seeks to reduce the severe morbidity and mortality associated with infections caused by various fungal pathogens.

Radiant Biotherapeutics is an innovative biotechnology company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by creating multi-functional biologics designed to address challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging the principles of avidity and enhanced binding power, Radiant Biotherapeutics enables healthcare professionals to deliver potent therapies that have the potential to transform treatment outcomes for patients. The company's commitment to pioneering these advanced therapeutics positions it at the forefront of the biotherapeutics field, striving to unlock new avenues for patient care.

Phenomic AI Inc. is a biotechnology company based in Toronto, Canada, focused on accelerating drug discovery and developing therapies for cancer. Founded in 2017, Phenomic AI has created an innovative drug discovery platform that leverages artificial intelligence and computer vision to analyze phenotypic assays. This platform enables the examination of complex disease models, including high-content co-culture and three-dimensional assays, allowing pharmaceutical companies to discover and optimize therapeutics more efficiently. By specializing in targeting tumor stroma, Phenomic AI aims to enhance the drug development process, making it easier for researchers to identify effective medicines.

Hypercare is a healthcare coordination platform designed to enhance clinical communication and collaboration among healthcare providers. Recognizing the challenges posed by traditional communication methods, such as switchboards and pagers, the platform aims to improve patient-centered care by enabling seamless connections across various healthcare settings, including hospitals, long-term care facilities, community care organizations, and family practices. Hypercare addresses the inefficiencies of existing communication channels by minimizing interruptions and allowing healthcare professionals to communicate and locate one another quickly and effectively. This innovative approach mitigates the risks associated with using non-secure messaging applications, thereby protecting patient privacy and reducing medico-legal liabilities for healthcare providers and institutions.

Phycus Biotechnologies Inc., based in Toronto, Canada, specializes in producing ingredients for the cosmetics and personal care industries, including bioglycolic acid and AHA ferment lysate. Established in 2017, the company also operates a bio-conversion platform that utilizes microbial technology and metabolic engineering techniques to capture and convert carbon dioxide from large-scale emitters. This innovative approach enables the transformation of CO2 into high-value chemical building blocks, which can be utilized in various industrial applications. By providing an alternative method for recycling carbon dioxide into fuels and chemicals, Phycus Biotechnologies aims to contribute to the reduction of greenhouse gas emissions and promote sustainability in industrial practices.

Reeddi is a climate technology company focused on innovating solutions for sustainable, clean, and affordable electricity production. Its primary goal is to provide electricity access where it currently lacks. Reeddi engages in clean energy generation, distribution, and storage, offering its technology to individuals, households, and businesses in energy-poor regions. The company's innovative device delivers energy in both AC and DC formats, enabling it to power various devices from phones to home electronics while reducing the health and environmental impacts associated with fuel-based alternatives.

Bright Angel Therapeutics is a biopharmaceutical company focused on developing innovative treatments for drug-resistant and life-threatening fungal infections. The company aims to enhance the efficacy of existing antifungal therapies and combat drug resistance by specifically targeting the stress responses that fungi rely on for survival, virulence, and resistance to treatment. By addressing the challenges posed by the frequent emergence of clinical resistance, Bright Angel Therapeutics seeks to reduce the severe morbidity and mortality associated with infections caused by various fungal pathogens.

Odaia is a developer of an AI-powered Customer Data Platform tailored for the Life Sciences industry. The company has pioneered the integration of process mining, customer journey mapping, and artificial intelligence to provide goal-driven commercial insights and process automation. Through its predictive analytics and commercial insights platform, Odaia assists clients in facilitating personalized selling. This innovative solution enables pharmaceutical commercial teams to analyze data effectively, ensuring that therapeutics reach the patients who need them. Odaia's focus on leveraging advanced technology positions it as a leader in enhancing the efficiency and effectiveness of sales strategies within the healthcare sector.

CoHealth is a content creation and distribution platform tailored for health organizations, including providers and systems. The company enables these organizations to create, transform, and disseminate health-related content effectively to engage health consumers. Its platform offers features such as hospital information, medication reminders, and personalized task and schedule recommendations. By partnering personal health managers with healthcare providers, CoHealth develops customized digital care pathways for various health conditions, ensuring that patients receive comprehensive aftercare support upon leaving the hospital. This approach enhances patient engagement and improves health outcomes by streamlining access to essential health information and resources.

Bright Angel Therapeutics is a biopharmaceutical company focused on developing innovative treatments for drug-resistant and life-threatening fungal infections. The company aims to enhance the efficacy of existing antifungal therapies and combat drug resistance by specifically targeting the stress responses that fungi rely on for survival, virulence, and resistance to treatment. By addressing the challenges posed by the frequent emergence of clinical resistance, Bright Angel Therapeutics seeks to reduce the severe morbidity and mortality associated with infections caused by various fungal pathogens.

Notch Therapeutics Inc. is an immune cell therapy company focused on developing gene-edited allogenic T cell therapies for cancer treatment. Founded in 2018 and headquartered in Toronto, Canada, the company specializes in induced pluripotent stem cell (iPSC) AlloCAR therapy products targeting non-Hodgkin lymphoma, leukemia, and multiple myeloma. Notch Therapeutics has created a proprietary T-cell production platform that allows for precise control of Notch signaling, a critical factor in T-cell development. This innovative approach addresses key limitations in cell therapy development, enabling the design and manufacture of a consistent and limitless supply of therapeutic T cells. The technology empowers healthcare professionals to engineer stem cells tailored to the complex biology of various diseases, thereby enhancing the efficacy of cell therapies.

Flybits Inc. is a Toronto-based company that specializes in a context-aware experience development platform tailored for the financial services sector. The platform enables banks to create personalized digital interactions by delivering relevant content, products, and offers to customers based on their specific needs during critical moments. By leveraging the vast amounts of available data and incorporating advanced sensing capabilities, Flybits allows financial institutions to enhance customer engagement while maintaining privacy. It empowers these institutions to design, launch, and evaluate data-driven consumer experiences, thereby fostering stronger relationships between individuals and their banks. The company is recognized for its innovative approach to contextual experiences, making it a leader in customer experience solutions for financial services.

Cohesys is a biotechnology company focused on developing innovative surgical adhesives inspired by natural processes. The company specializes in creating biodegradable bone tapes designed to aid in the healing of facial fractures. Its advanced flexible polymer tape and bio-inspired adhesive system are engineered to provide strength comparable to titanium screws, thereby enhancing the efficiency of craniomaxillofacial fracture fixation procedures. By simplifying the fixation process and reducing the associated risks, Cohesys aims to improve patient outcomes and minimize complications linked to bone fractures.

Mutuo Health Solutions is a developer of artificial intelligence-based medical devices that enhance the interaction between patients and clinicians. The company utilizes AI technology to record dialogues using any microphone, enabling the automatic generation of clinical notes and electronic medical record actions in real time. By leveraging advanced speech recognition and natural language processing, Mutuo Health Solutions allows medical professionals to concentrate on patient care rather than administrative tasks, ultimately improving the efficiency of healthcare delivery.

Bitnobi is a software company that specializes in designing and developing data-sharing platforms targeted primarily at the healthcare and finance sectors. The company's innovative platform allows for secure and privacy-protected access to large datasets, eliminating the need for data duplication. By enabling clients to launch data jobs directly and share access to data without creating copies of the original source, Bitnobi streamlines the process of data management and sharing. In addition to its core platform, the company offers services in data, cloud computing, and cybersecurity, aiming to enhance the overall efficiency and security of data handling for its clients.

Micellae Delivery Systems is a pharmaceutical manufacturing company specializing in advanced drug delivery systems aimed at enhancing the solubility and bioavailability of fat-soluble compounds, particularly cannabinoids. The company provides innovative, intellectual property-protected formulation platforms that enable the development of various dosage forms, including liquids, concentrates, gels, and powders. These formulations cater to a wide range of applications in medical and recreational cannabis, as well as pharmaceuticals, nutraceuticals, and cosmetics. Micellae Delivery Systems focuses on delivering cost-effective, healthy, and sustainable technology to its clients, positioning itself as a leader in the cannabis product market.

Lorica Cybersecurity specializes in advanced encryption technologies that facilitate secure and privacy-preserving data analytics for enterprises. The company's cloud-based platform utilizes machine learning and cryptography, including fully homomorphic encryption, to enable organizations to interact with encrypted data securely across their value chain. This approach allows enterprises to collaborate seamlessly, conduct data discovery, and generate insights without exposing sensitive information to risk. By addressing data breach risks and enhancing regulatory compliance for private datasets, Lorica empowers organizations to harness the full value of their data while protecting privacy and intellectual property in a digital-first landscape.

Nuro Corp, founded in 2017 and based in Waterloo, Canada, specializes in developing neurologically-powered communication software designed to assist doctors and patients. The company offers a range of products under its Neural Operating System (NUOS), which enables instant communication and computing through brain signals, eliminating the need for invasive procedures. Key offerings include NUOS ALS for ALS patients, NUOS TRAUMA for individuals with tetraplegia, and NUOS STROKE for stroke victims. Additionally, NUOS AI provides immediate access to insights derived from neurological and behavioral data, facilitating enhanced communication for incapacitated patients in various healthcare settings, including post-surgery, intensive care units, nursing homes, and rehabilitation facilities.

Appulse Power Inc. is a Toronto-based company that specializes in the design and manufacture of application-specific integrated circuits (ASIC) focused on semiconductor technology. Founded in 2015, the company has developed innovative power management solutions aimed at enhancing AC/DC power conversion efficiency. Appulse Power's products are designed to be lightweight and compact, addressing the growing demand for smaller and more integrated electronic devices while reducing power losses. Their technology consolidates multiple electronic device chargers into a single unit, making it particularly relevant for the Internet of Things and smart energy markets. By pushing the boundaries of traditional power conversion technology, Appulse Power aims to deliver higher efficiency and lower costs compared to existing solutions.

Upchain is a provider of cloud-based product lifecycle management (PLM) and product data management (PDM) solutions, established in 2015. The company aims to transform PLM by making it accessible to all users across the supply chain, rather than just large multinational corporations. Upchain's software facilitates collaboration within decentralized product value chains, offering features such as item management, version control, change management, bills of materials management, file compliance, and integration with computer-aided design tools. By focusing on creating an interconnected supply chain, Upchain seeks to simplify complex processes, enabling manufacturers to enhance revenue, reduce costs, and improve product quality.

Dalriada Therapeutics Inc. is a Canadian biotechnology company, incorporated in 2016 and headquartered in Mississauga. The company specializes in the development of novel small molecule inhibitors that target various medical conditions, including oncology, pain modulation, and neurodegenerative or neuroinflammatory disorders. Dalriada employs a TURN-KEY model that aligns research and development efforts with business and intellectual property strategies, thereby supporting global innovators in the pharmaceutical sector.

Zucara Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutics to prevent hypoglycemia, or low blood sugar, in patients with diabetes. Established in 2014 and headquartered in Toronto, Canada, with an additional office in Vancouver, Zucara is pioneering a once-daily treatment that aims to regulate the hormone somatostatin in the pancreas. This treatment specifically targets somatostatin type 2 receptors, which are not effectively controlled in patients with Type 1 diabetes. Zucara's approach presents a significant advancement in diabetes care by functioning as a preventative measure against hypoglycemia, contrasting with existing therapies that only provide rescue during acute episodes. Through its pre-clinical technology, Zucara Therapeutics aims to restore natural glucose levels in the blood, ultimately enhancing the quality of life for individuals living with diabetes.

Bitnobi is a software company that specializes in designing and developing data-sharing platforms targeted primarily at the healthcare and finance sectors. The company's innovative platform allows for secure and privacy-protected access to large datasets, eliminating the need for data duplication. By enabling clients to launch data jobs directly and share access to data without creating copies of the original source, Bitnobi streamlines the process of data management and sharing. In addition to its core platform, the company offers services in data, cloud computing, and cybersecurity, aiming to enhance the overall efficiency and security of data handling for its clients.

Hypercare is a healthcare coordination platform designed to enhance clinical communication and collaboration among healthcare providers. Recognizing the challenges posed by traditional communication methods, such as switchboards and pagers, the platform aims to improve patient-centered care by enabling seamless connections across various healthcare settings, including hospitals, long-term care facilities, community care organizations, and family practices. Hypercare addresses the inefficiencies of existing communication channels by minimizing interruptions and allowing healthcare professionals to communicate and locate one another quickly and effectively. This innovative approach mitigates the risks associated with using non-secure messaging applications, thereby protecting patient privacy and reducing medico-legal liabilities for healthcare providers and institutions.

Structura Biotechnology specializes in advanced cryo-electron microscopy image analysis, providing a platform that facilitates the detailed study of biological systems. The company's technology employs machine learning to assist researchers in analyzing cryo-EM data and reconstructing 3D atomic structures of proteins, biomolecular complexes, and viruses. This capability is particularly valuable for investigating membrane proteins, ion channels, G protein-coupled receptors (GPCRs), and drug targets with ligands bound. By offering proprietary algorithms and design tools, Structura Biotechnology aims to enhance the drug discovery process, enabling healthcare professionals to develop new medicines more efficiently.

Appulse Power Inc. is a Toronto-based company that specializes in the design and manufacture of application-specific integrated circuits (ASIC) focused on semiconductor technology. Founded in 2015, the company has developed innovative power management solutions aimed at enhancing AC/DC power conversion efficiency. Appulse Power's products are designed to be lightweight and compact, addressing the growing demand for smaller and more integrated electronic devices while reducing power losses. Their technology consolidates multiple electronic device chargers into a single unit, making it particularly relevant for the Internet of Things and smart energy markets. By pushing the boundaries of traditional power conversion technology, Appulse Power aims to deliver higher efficiency and lower costs compared to existing solutions.

QD Solar Inc., founded in 2014 and based in Toronto, Canada, is a company that develops advanced photovoltaic cells using colloidal quantum dot technology. The company's innovative approach combines efficient silicon solar cells with infrared solar cells in a hybrid architecture to capture more of the solar spectrum than traditional silicon cells alone. This technology aims to enhance the performance of solar cells, making them more cost-effective and efficient. QD Solar was spun off from the University of Toronto and focuses on creating new nanomaterial semiconductors to promote sustainable development and increase the use of renewable energy sources.

Hypercare is a healthcare coordination platform designed to enhance clinical communication and collaboration among healthcare providers. Recognizing the challenges posed by traditional communication methods, such as switchboards and pagers, the platform aims to improve patient-centered care by enabling seamless connections across various healthcare settings, including hospitals, long-term care facilities, community care organizations, and family practices. Hypercare addresses the inefficiencies of existing communication channels by minimizing interruptions and allowing healthcare professionals to communicate and locate one another quickly and effectively. This innovative approach mitigates the risks associated with using non-secure messaging applications, thereby protecting patient privacy and reducing medico-legal liabilities for healthcare providers and institutions.

Fibrocor Therapeutics L.P. is a biotechnology company based in Toronto, Canada, established in 2017. The company specializes in developing tissue-specific therapeutics aimed at treating the underlying causes of fibrotic diseases affecting the kidneys and other organs. Fibrocor focuses on disease-modifying therapeutics for fibrosis and has identified a lead program for which it collaborates with Evotec to develop novel molecules. Utilizing patient-derived tissue samples, Fibrocor's innovative platform uncovers critical pathways in the fibrogenic process, facilitating the identification of new disease targets and the development of a comprehensive pipeline of therapeutics.

LegUp Computing Inc., founded in 2015 by Dr. Andrew Canis, Dr. Jongsok Choi, Ruolong Lian, and Professor Jason Anderson, develops a cloud platform that facilitates programming, deployment, scaling, and management of field-programmable gate array (FPGA) devices for accelerating high-performance applications such as low-latency database processing and machine learning workloads. Originally developed at the University of Toronto, LegUp's platform offers a novel programming model enabling threaded C/C++ software to target FPGAs connected to high-bandwidth networks efficiently. As of October 9, 2020, LegUp operates as a subsidiary of Microchip Technology Incorporated, headquartered in Toronto, Canada.

HippoCamera is an online application focused on enhancing the memory recall of elderly individuals through engaging reminiscence activities. The platform is designed to simulate the functions of the hippocampus, a crucial brain region responsible for memory. By combining enjoyable activities with proven cognitive benefits, HippoCamera aims to improve users' ability to remember and reflect on significant events in their lives, ultimately fostering mental wellness and enriching their daily experiences.

Zucara Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutics to prevent hypoglycemia, or low blood sugar, in patients with diabetes. Established in 2014 and headquartered in Toronto, Canada, with an additional office in Vancouver, Zucara is pioneering a once-daily treatment that aims to regulate the hormone somatostatin in the pancreas. This treatment specifically targets somatostatin type 2 receptors, which are not effectively controlled in patients with Type 1 diabetes. Zucara's approach presents a significant advancement in diabetes care by functioning as a preventative measure against hypoglycemia, contrasting with existing therapies that only provide rescue during acute episodes. Through its pre-clinical technology, Zucara Therapeutics aims to restore natural glucose levels in the blood, ultimately enhancing the quality of life for individuals living with diabetes.

Xor Labs Toronto is a pioneering company in the field of personalized medicine focused on organ transplantation, specifically targeting lung transplants. The company develops innovative medical devices that enhance the availability of donated lungs for transplantation, addressing the critical needs of patients suffering from severe respiratory diseases such as pulmonary fibrosis, cystic fibrosis, pulmonary hypertension, and chronic obstructive pulmonary disease. By advancing the technology associated with lung transplantation, Xor Labs aims to significantly reduce mortality rates among individuals awaiting this life-saving procedure, ultimately transforming the landscape of organ donation and transplantation worldwide.

Purchs is an omnichannel platform that streamlines the sourcing of goods and billing management for merchants. By utilizing conversational commerce and artificial intelligence, the platform allows merchants to scan product UPC codes with their smartphones and complete transactions via text, eliminating the need for logins or traditional checkout processes. For vendors, Purchs provides a comprehensive e-commerce solution tailored for B2B retail sales, enabling them to list products with customized pricing, manage inventory and delivery, handle customer relationships, and automate payment processes—all from a single interface. Additionally, the platform facilitates wholesale distribution and simplifies direct-to-store delivery, helping clients lower their distribution costs and reduce their carbon footprint.

Radialis is a developer of an organ-targeted positron emission tomography (PET) imaging system that focuses on high-definition and low-dose applications in oncology, neurology, and cardiology. The company’s technology significantly enhances the efficiency of radiotracer detection compared to traditional PET systems, achieving a tenfold improvement. This advanced imaging system has received broad FDA clearance in the United States for the imaging and measurement of injected positron-emitting radiopharmaceuticals. Its primary application lies in high-resolution imaging of primary solid tumors, serving as a valuable adjunct to conventional staging PET/CT without the need for additional radiotracer. Additionally, Radialis is actively engaged in developing targeted early detection methods for cancer and Alzheimer's disease, particularly within high-risk populations, emphasizing low-dose imaging techniques to improve patient safety.

Knitt Labs is a Toronto-based technology start-up focused on addressing energy waste through innovative management solutions. The company develops technology that leverages big data to enhance electricity consumption management. By utilizing Internet of Things (IoT) devices, Knitt Labs aims to provide clients with tools to optimize their energy usage, ultimately reducing waste and resulting in cost savings. Their approach seeks to redefine how individuals and organizations use and manage power, contributing to more sustainable energy practices.

Crowd2Know operates in the area of stakeholder engagement. We bring organizations operating in urban development closer to their customers, citizens and end users by providing a platform for listening, analyzing, and effectively communicating with each other. We achieve this through a systematic process using a suite of software products and expert services that facilitate the analysis of social media, project documents, and other records. Using our urban infrastructure knowledge base and set of analysis algorithms we provide a real-time mapping of stakeholders, discussion topics, and relative alignment of opinions which drive consistent recommendations for decision makers.

Blue J is a developer of a legal research platform that aims to assist legal professionals in predicting court outcomes. The platform employs machine learning and artificial intelligence to analyze historical judicial decisions and identify patterns that can inform predictions about future cases. By leveraging this data alongside relevant case law, Blue J's technology enhances productivity and allows legal teams to concentrate on higher-value tasks, ultimately saving time and reducing costs associated with legal research.

Onyx Motion is a company focused on developing innovative sports coaching applications for both Apple and Android smartwatches. In addition to its digital offerings, the company manufactures paddle sports equipment tailored for outdoor enthusiasts. Its product line includes a variety of paddleboards and gear, complemented by instructional content aimed at helping individuals improve their performance and enjoyment in water sports. Through its commitment to enhancing athletic experiences, Onyx Motion serves a diverse audience of sports enthusiasts.

PhenoTips is a computer software company based in Ontario, Canada, that specializes in solutions for clinical genetics and phenotyping. Founded in 2014, the company develops software designed to enhance diagnostic accuracy and standardize the recording of phenotypes. Its products are tailored for clinical environments and can be seamlessly integrated with existing electronic health records. By leveraging advanced technology, PhenoTips aims to support healthcare professionals in utilizing genomic medicine for improved clinical decision-making and diagnosis.

FlowJEM is a developer of polymer microfluidic technology that specializes in the rapid and economical prototyping of robust microfluidic devices. The company’s innovative technology facilitates the production of high-quality plastic microfluidic components using various thermoplastic materials. These materials are selected based on critical factors such as chemical compatibility, optical transparency, and temperature stability, ensuring that clients receive tailored solutions for their specific applications. FlowJEM's expertise supports researchers and engineers in advancing their projects in microfluidics, contributing to developments in various fields.

ScarX Therapeutics Inc. is a biotechnology company focused on discovering and developing treatments for dermal scarring, also known as fibrosis. Founded in 2012 and based in Toronto, Canada, ScarX is advancing its lead product, SCX-001, a topical prescription cream designed to treat and prevent post-surgical scarring. The active ingredient in SCX-001, nefopam, has been identified as an effective anti-scarring agent. ScarX aims to address a significant unmet need, as millions of surgical patients globally experience complications from scarring, which can lead to both physical and psychological challenges. The company has recently completed preclinical studies and is preparing to initiate Phase I/IIa clinical trials for SCX-001. ScarX targets the cosmetic and reconstructive plastic surgery markets, which represent a substantial portion of the overall market for anti-scarring treatments, estimated to be valued at several billion dollars annually in the U.S. alone.

WaveCheck — a painless, non-surgical clinical technique developed by a Sunnybrook Health Sciences Centre oncologist and a Ryerson University physicist and supported by MaRS Innovation — is poised to transform chemotherapy response monitoring for women with breast cancer. WaveCheck combines traditional ultrasound with new software to detect responses to chemotherapy in breast cancer tissues. By making better, more accurate information available about a woman's response to her chemotherapy treatment in weeks, rather than months, WaveCheck creates greater transparency through dialogue between a women and her doctors, empowering her to participate in discussions about whether a given chemotherapy treatment is effective.

AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, founded in 2016. The company is focused on developing an innovative injectable hydrogel platform technology designed to enhance drug delivery and improve patient outcomes in various medical applications, particularly in post-surgical pain management, cancer treatment, and other challenging therapeutic areas. AmacaThera's technology features a unique fast-gelling material that liquefies under mechanical force, consisting of a reversible blend of hyaluronan and methylcellulose. This approach allows for localized and sustained drug delivery, potentially reducing postoperative pain and addressing other medical needs effectively.

CoHealth is a content creation and distribution platform tailored for health organizations, including providers and systems. The company enables these organizations to create, transform, and disseminate health-related content effectively to engage health consumers. Its platform offers features such as hospital information, medication reminders, and personalized task and schedule recommendations. By partnering personal health managers with healthcare providers, CoHealth develops customized digital care pathways for various health conditions, ensuring that patients receive comprehensive aftercare support upon leaving the hospital. This approach enhances patient engagement and improves health outcomes by streamlining access to essential health information and resources.

Nuralogix is a healthcare technology company specializing in Affective AI. It has developed Transdermal Optical Imaging (TOI™), a patented technology using conventional cameras to extract facial blood flow information for health monitoring. The company's flagship product, Anura™, is a contactless health tracking app that measures blood pressure, heart rate, stress levels, BMI, and cardiovascular disease risks with medical-grade accuracy using only a smartphone camera.

Ardra Inc. is a renewable chemicals company based in Toronto, Canada, specializing in the production of petroleum-free specialty chemicals for the personal care and cosmetics industry. Utilizing technology developed at the University of Toronto, Ardra employs model-guided metabolic engineering and synthetic biology to create biocatalysts that convert renewable resources into essential chemicals. The company's flagship product is 1,3-butanediol, a sustainable alternative to petroleum-based counterparts, which is utilized in various applications including cosmetics, food, polymers, and pharmaceuticals. With the cosmetics sector relying heavily on petroleum chemicals, valued at approximately $2.6 billion, Ardra aims to provide environmentally friendly solutions that stabilize and sustain the supply chain while reducing ecological impact.

Encycle Therapeutics, Inc. is a biotechnology company based in Toronto, Canada, that focuses on developing innovative drug candidates using its proprietary platform technology for the rapid synthesis of drug-like macrocycles and membrane-permeable nacellins. These nacellins are designed to target challenging intracellular protein-protein interactions, offering a potential alternative to traditional small molecules and biologics, such as monoclonal antibodies. The company has established collaborations with various pharmaceutical firms to build a screening library of nacellins, many of which demonstrate cell-permeable and drug-like characteristics. Encycle is actively pursuing the independent development of nacellins aimed at specific targets, including integrin alpha-4-beta-7 for inflammatory bowel disease and SMURF2 for fibrosis. Its lead program seeks to create orally bioavailable inhibitors of integrin alpha-4-beta-7 that promise improved safety and reduced immunogenicity compared to existing biologics targeting this protein.

LegWorks, Inc. is a company that designs and manufactures prosthetic knee joints and various components for complete prosthetic leg solutions aimed at lower-limb amputees globally. Founded in 2013 and headquartered in Buffalo, New York, LegWorks operates as a for-profit social enterprise with a vision to provide accessible prosthetic solutions regardless of geographical location, social status, or financial means. The company's innovative prosthetic knee joint features a locking mechanism that prevents bending, enhancing mobility and promoting independence for its users. By employing tiered pricing strategies, LegWorks aims to maximize the distribution of its products across diverse markets, ensuring that individuals in both developed and developing regions can benefit from their technology.

Syncadian Inc. is a technology company focused on developing software solutions in the fatigue modeling and management sector. Initially, the company created a mobile application designed to assist soldiers in the Canadian military in preventing jetlag. Syncadian continues to expand its product offerings, exploring applications for various groups, including shift workers and cancer patients. The company's vision centers on creating fatigue management solutions that aim to reduce errors related to fatigue, enhance productivity, and enable individuals to monitor and optimize their sleep quality and patterns. Through its innovative approach, Syncadian seeks to address the challenges posed by fatigue in various professional and personal contexts.

ChipCare Corporation, established in 2009 and headquartered in Toronto, Canada, specializes in developing and manufacturing point-of-care testing systems for health applications. The company's core product is a handheld cell analyzer system designed to conduct various blood tests from a single drop of sample, including cell counting, protein/enzyme detection, and pathogen identification. ChipCare aims to make advanced blood testing accessible globally by offering an integrated solution comprising a handheld reader and disposable test slides, with primary revenue generated through the sale of these consumables. The company's innovative detection technique enables multiplexed testing, addressing clinical challenges in both resource-rich and limited settings.

Flatfab offers a digital modeling and fabrication software that facilitates the design and creation of 3D objects using traditional craftsmanship techniques instead of 3D printing. The software integrates interactive verification and real-time model testing, allowing users to work seamlessly with common materials such as paper, plastic, wood, steel, and stone. By utilizing laser cutting technology and CNC machines, Flatfab enables designers and hobbyists to translate their 2D ideas into tangible 3D forms efficiently and cost-effectively. The platform is tailored for those who wish to combine their design skills with accessible fabrication methods, making the process of bringing complex ideas to life more fluid and practical.

Nvest is an Internet platform that helps people become smarter investors. Anyone is free to share investment opinions. Nvest evaluates people’s credibility based on the accuracy of their opinions because actual performance speaks louder than credentials. Nvest is currently focusing on stock markets, and will be expanded to many possible investment types. People can express their opinions as buy and sell ratings. The accuracy of each opinion depends on its correctness, magnitude of impact and industry. Nvest wants to consolidate and present only the very valuable investment information to retail investors at the right time. People will be able to access Nvest with any Internet devices. Visit http://www.nvest.me for open beta!

Forbius, also known as Formation Biologics, is a clinical-stage biopharmaceutical company focused on designing and developing innovative therapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, the company specializes in creating agents that target critical biological pathways, specifically the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. By leveraging advanced protein engineering technologies and a deep understanding of biology, Forbius aims to produce highly effective inhibitors with unique mechanisms of action, ultimately striving to improve patient outcomes and transform lives.

Vasomune Therapeutics is a private biotechnology company focused on developing therapies for diseases related to blood vessel dysfunction and destabilization. The company aims to address the consequences of dysfunctional vasculature, which can lead to exacerbated inflammatory responses in various conditions, including cardiovascular, renal, pulmonary, and cancer-related diseases. Its lead compound, Vasculotide, is a Tie2 receptor agonist that has shown promising therapeutic effects in multiple disease contexts tied to vascular dysfunction. Founded in 2012 as a spin-out from MaRS Innovation and Sunnybrook Hospital at the University of Toronto, Vasomune is leveraging robust academic research to translate into clinical applications. The company’s initial efforts are directed towards addressing acute and chronic kidney diseases, with a particular focus on treating Acute Kidney Injury (AKI), a significant unmet medical need, supported by strong preclinical evidence indicating that vascular dysfunction plays a critical role in the condition.

Granata Decision Systems specializes in developing decision support software aimed at enhancing organizational and individual decision-making processes. Its platform offers real-time optimization and scenario analysis capabilities tailored for large-scale, data-driven marketing challenges. By utilizing patent-pending algorithms, Granata's technology enhances the efficacy of machine learning and analytics, enabling users to distill insights from multiple analyses. This focus allows organizations to concentrate on the factors that align with their overarching objectives, facilitating complex, data-driven group decisions. Through its innovative solutions, Granata empowers clients to gather preferences and evaluate decisions, ultimately maximizing value for relevant stakeholders.

Whirlscape is a technology company that develops predictive messaging software for mobile devices. It specializes in creating natural language models that anticipate and suggest text, emojis, stickers, GIFs, and other expressive content during conversations. The company's flagship product is a mobile keyboard application designed to enhance the texting experience by minimizing the keyboard to a single line continuum, allowing users to see more of their screen while typing faster and more accurately.

WaveCheck — a painless, non-surgical clinical technique developed by a Sunnybrook Health Sciences Centre oncologist and a Ryerson University physicist and supported by MaRS Innovation — is poised to transform chemotherapy response monitoring for women with breast cancer. WaveCheck combines traditional ultrasound with new software to detect responses to chemotherapy in breast cancer tissues. By making better, more accurate information available about a woman's response to her chemotherapy treatment in weeks, rather than months, WaveCheck creates greater transparency through dialogue between a women and her doctors, empowering her to participate in discussions about whether a given chemotherapy treatment is effective.

ChipCare Corporation, established in 2009 and headquartered in Toronto, Canada, specializes in developing and manufacturing point-of-care testing systems for health applications. The company's core product is a handheld cell analyzer system designed to conduct various blood tests from a single drop of sample, including cell counting, protein/enzyme detection, and pathogen identification. ChipCare aims to make advanced blood testing accessible globally by offering an integrated solution comprising a handheld reader and disposable test slides, with primary revenue generated through the sale of these consumables. The company's innovative detection technique enables multiplexed testing, addressing clinical challenges in both resource-rich and limited settings.

BlueDot Inc. is a data analytics company based in Toronto, Canada, specializing in infectious disease monitoring and response. Founded in 2008 and formerly known as BioDiaspora Inc., the company provides a global early warning system that tracks and analyzes the spread of over 190 infectious diseases. By integrating artificial intelligence with human expertise, BlueDot combines diverse datasets—ranging from disease outbreak reports and healthcare facility locations to climate data and population demographics—to deliver critical insights. This enables governments, businesses, and healthcare professionals to identify potential threats, anticipate future outbreaks, and respond effectively without overreacting or underreacting.

Crowdmark, Inc. is an education technology company based in Toronto, Canada, founded in 2012. It provides a web-based application designed to facilitate document assessment through a paper-to-cloud bridge and a streamlined marking workflow. The platform leverages artificial intelligence to support instructors in administering and grading both online and in-class assessments across various educational levels, including primary, secondary, and tertiary education. By enabling educators to quickly grade paper-based and digital assignments, Crowdmark enhances the efficiency of the grading process while generating valuable insights into learning performance. The company's mission is to improve educational outcomes by redefining assessment as a dialogue between teachers and students, ultimately fostering better learning experiences for all stakeholders involved.

Treata Smart Solutions specializes in caregiving technology aimed at assisting memory-impaired adults. Founded in 2012 and headquartered in Toronto, Ontario, the company offers three main products: The Smart Lost Item Finder, The Smart Wandering Assistant, and The Smart Reminder. These devices leverage existing smartphone technology, incorporating patent-pending hardware and software to enhance their functionality. The company's emergency response system is particularly valuable for caregivers, as it provides real-time location updates and alerts via a connected smartphone app, ensuring that caregivers are informed about the whereabouts and safety of their loved ones.

Root2Crown is a medical technology company focused on improving dental health assessment and diagnosis through innovative hardware and software solutions. The company aims to streamline the dental risk assessment process, making it more efficient, reliable, and accessible for dental schools, practices, and the general public. Its technology facilitates the tracking of caries progression over time for each patient, enabling optimal scheduling of follow-up appointments. By enhancing the communication of dental risk assessments, Root2Crown seeks to empower patients and dental professionals alike, ultimately promoting better dental health outcomes.

TrendMD Inc. is a Toronto-based company founded in 2013 that specializes in providing a content recommendation engine tailored for scholarly publishers. The platform offers personalized article recommendations, primarily targeting medical professionals and researchers. By partnering with prominent scientific publishers, such as Elsevier and Oxford University Press, TrendMD integrates a line of JavaScript code into journal websites, enabling the display of related articles at the bottom of each page. This service aims to enhance the accessibility and dissemination of peer-reviewed content, serving approximately 500 million recommendations to over 60 million readers each month. TrendMD utilizes a sophisticated algorithm to create individual profiles for readers, thereby facilitating quicker access to relevant scientific discoveries and accelerating the advancement of knowledge within the academic community.

Crowdmark, Inc. is an education technology company based in Toronto, Canada, founded in 2012. It provides a web-based application designed to facilitate document assessment through a paper-to-cloud bridge and a streamlined marking workflow. The platform leverages artificial intelligence to support instructors in administering and grading both online and in-class assessments across various educational levels, including primary, secondary, and tertiary education. By enabling educators to quickly grade paper-based and digital assignments, Crowdmark enhances the efficiency of the grading process while generating valuable insights into learning performance. The company's mission is to improve educational outcomes by redefining assessment as a dialogue between teachers and students, ultimately fostering better learning experiences for all stakeholders involved.

XLV Diagnostics Inc., located in Thunder Bay, Canada, specializes in the development and manufacturing of advanced digital mammography machines designed to provide low-cost screening for early-stage breast cancer. The company's innovative X-ray light valve technology is integrated into custom-made mammography systems, making them particularly suitable for emerging markets such as China, India, and Brazil, where breast cancer incidence is rising alongside a lack of access to effective diagnostic tools. By focusing on affordability and quality, XLV Diagnostics aims to enhance early detection services in developing countries, thereby improving healthcare outcomes for women at risk of breast cancer.

eQOL is a developer of a patient-centric medical platform aimed at enhancing chronic care management by transitioning care from hospital settings to patients' homes. The company focuses on empowering individuals to manage their daily clinical tasks independently, thereby improving the quality of care and fostering patient autonomy. By leveraging innovative technologies and streamlined processes, eQOL seeks to optimize healthcare delivery efficiency while reducing associated costs. The company's solutions are designed to simplify the medical process and alleviate the intimidation often felt by patients, ultimately supporting their self-care and well-being amid an aging population and increasing healthcare demands.

Kaypok is a technology company specializing in unstructured data analytics and information management. It develops advanced software designed to analyze diverse data sources, including public social media, proprietary internal data, customer surveys, emails, and blogs. By extracting actionable insights and sentiments from this data, Kaypok enables enterprises to understand the underlying information that drives analytics. The company's solutions enhance user experience and facilitate better decision-making by transforming unstructured data into valuable knowledge. Through its innovative approach, Kaypok addresses the growing need for effective data analysis in various business contexts.

Bedside Clinical Systems (BCS) facilitates the deployment of innovations in healthcare supporting clinicians in providing safer and more effective care.

CoursePeer is a developer of a cloud-based suite of learning tools designed to enhance performance and productivity in both academic and corporate environments. Its highly scalable and fully integrated solutions support blended learning, video content, quizzes, and live interactions, fostering collaboration through social networking features. The academic version caters to universities and colleges, allowing professors to efficiently deliver content and enhance communication with students, while also facilitating assessments and course reviews for accreditation purposes. In the corporate sector, CoursePeer provides tools for employee training, certification, intranet use, and long-term performance assessment, enabling organizations to manage learning and development effectively.

Kapplex Inc. is a Toronto-based company that designs and manufactures advanced point-of-care diagnostic platforms. Established in 2012, the company focuses on enabling the rapid and accurate diagnosis of common infectious diseases in various healthcare settings, including retail clinics, doctor's offices, urgent care units, and emergency rooms. Kapplex leverages a proprietary Digital Microfluidic (DMF) technology, originally developed in a University of Toronto lab, which simplifies and automates traditional sample preparation and analysis processes on an economical, single-chip device. This innovative approach aims to enhance clinical decision-making at the point of care, ultimately improving treatment outcomes while reducing healthcare costs.

OtoSim is a medical simulation platform specifically designed for training in otoscopy and ophthalmoscopy. Developed by a team of clinicians, educators, and engineers, OtoSim addresses the deficiencies in current otoscopic training methods. The innovative device, which was validated through scientific study, offers a comprehensive teaching tool that ensures verifiable learning outcomes, enhancing diagnostic efficiency among students. The platform allows for the connection of multiple units to a single trainer laptop, facilitating group training in medical schools. By streamlining the educational process, OtoSim aims to improve the accuracy and reliability of ear and eye diagnostic skills among future healthcare professionals.

Xagenic Inc., based in Toronto, Canada, specializes in developing molecular diagnostics technology for rapid, decentralized testing. Their aim is to empower clinicians with on-demand, near-patient molecular testing capabilities, enabling timely treatment decisions and improving patient care while reducing healthcare costs. Xagenic's platform detects nucleic acids from clinical samples without the need for enzymes, delivering results in just 20 minutes. This allows for widespread diagnostic testing outside of traditional clinical laboratories, initially focusing on infectious disease tests.